| http://www.w3.org/ns/prov#value | - It is designed to be delivered via an optimized, small-droplet Investigational eFlow Nebulizer System or via PARI's paranasal drug delivery system, VibrENT. This provides the potential for the treatment of lower and upper respiratory diseases, such as asthma or sinusitis. ...Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with
|
